Edison Investment Research - Kape Technologies (KAPE) Kape Technologies - Intego deal adds Mac and anti-malware capability

Report

Edison Investment Research

Dan Ridsdale

Kape Technologies - Intego deal adds Mac and anti-malware capability

Kapeâ€™s acquisition of Intego for $16m looks a good fit. It broadens Kapeâ€™s portfolio by adding anti-malware software and significantly strengthening its Mac offering. We see good scope for sales synergies through cross-selling and leveraging Kapeâ€™s customer acquisition platform. The deal boosts our FY18 and FY19 EPS by 2% and 9% respectively, while synergies should strengthen beyond our forecast period.

24/07/2018 6 EN

Underlying

Kape Technologies

Kape Technologies is engaged in online digital product development and distribution and the provision of software platforms to the digital advertising industry. Co. operates through two segments: web and desktop, and mobile. Co.'s web and desktop segment comprises its Web applications development and Desktop application distribution platforms. Co.'s mobile segment operates its own white label Mobile media management platform, Ajillion, and its own Mobile Advertisement Network, DefinitiMedia.

See profile

IM00BQ8NYV14 London Stock Exchange Isle of Man

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Dan Ridsdale

Other Reports on these Companies

BusinessWire

ExpressVPN to Join Kape Technologies, with Shared Vision to Transform Privacy and Security

LONDON & DENVER--(BUSINESS WIRE)-- Kape Technologies PLC (KAPE: LSE) is pleased to announce that ExpressVPN will be joining the Kape family as part of a US$936 million deal. Combining Kape and ExpressVPN to create a premium consumer privacy and security player in the industry marks a key milestone in the rapidly growing digital privacy space. It also further positions Kape to define the next generation of privacy and security protection tools and services to return greater control over the digital sphere to consumers. This press release features multimedia. View the full release here: “We’ve ...

September 13, 2021 September 13, 2021 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Fundamental Research

Feasibility Study Results in December to be a Catalyst for this Junior

EUR 18.65

November 25, 2019 November 25, 2019 14 EN

Biodexa Pharmaceuticals - In a period of transition

FY23 was a transitional year for Biodexa, following the restructuring announced in March 2023 into a therapeutic company from a drug delivery specialist, and the implementation of cost-saving initiatives in light of the macroeconomic environment. The pipeline expansion primarily de-risks the business, partially fulfilled with the acquisition of lyn kinase activator tolimidone, for type 1 diabetes (T1D), in late 2023. Management estimates gross cash of £5.97m at end-FY23 to provide a runway into Q424, past the planned Phase IIa trial initiation for tolimidone. The next catalyst will likely be t...

3h / 16m 3h / 16m 1 EN

Toby Thorrington

Toby Thorrington

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

20h / 54m 20h / 54m 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

23h / 44m 23h / 44m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN